Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.62 USD | +2.70% | +2.24% | +55.09% |
04-11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
04-11 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.48 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.5 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+55.09% | 25.73B | - | ||
-2.32% | 90.45B | A- | ||
+3.68% | 41.45B | A- | ||
-10.90% | 33.57B | B- | ||
-19.56% | 14.73B | C | ||
-9.06% | 12.82B | B- | ||
-11.34% | 11.7B | D+ | ||
-43.53% | 11.44B | B | ||
+3.75% | 8.79B | B+ | ||
-6.32% | 8.35B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UCB Stock
- UCBJY Stock
- Ratings UCB SA